Vitamin D and Risk for Type 2 Diabetes in People With Prediabetes : A Systematic Review and Meta-analysis of Individual Participant Data From 3 Randomized Clinical Trials
Authors' conclusion
In adults with prediabetes, vitamin D was effective in decreasing risk for diabetes.
Study context
- Population
- Adults with prediabetes3 RCTs
- Comparison
- Oral vitamin D vs placebo
- Outcome
- Time to event for new-onset diabetes
Methodological detailsprespecified analyses, unadjusted and adjusted for key baseline variables, intention-to-treat, Trials were at low risk of bias
- Prespecified analyses, unadjusted and adjusted for key baseline variables
- Intention-to-treat
- Trials were at low risk of bias
Pooled result
As reported in the abstract
New-onset diabetes
Vitamin D vs PlaceboHazard ratio (95% CI)
Adjusted analyses; risk reduced by 15%
0.85(0.75–0.96)
- New-onset diabetes
- 3-year absolute risk reduction 3.3% (95% CI 0.6%–6.0%)
Further pooled results
| Outcome | Estimate | |
|---|---|---|
| Regression to normal glucose regulationLikelihood increased by 30% | rate ratio 1.30 (CI 1.16–1.46) | |
| New-onset diabetes, vitamin D recipients with intratrial mean serum 25(OH)D ≥125 nmol/L (≥50 ng/mL) vs 50 to 74 nmol/L (20 to 29 ng/mL)25(OH)D ≥125 nmol/Lvs 25(OH)D 50 to 74 nmol/LCholecalciferol reduced risk by 76% | HR 0.24 (CI 0.16–0.36) | |
| 0.10.31310Ratio (log scale) |
| Outcome | 3-year absolute risk reduction (CI) |
|---|---|
| New-onset diabetes, vitamin D recipients with intratrial mean serum 25(OH)D ≥125 nmol/L (≥50 ng/mL) vs 50 to 74 nmol/L (20 to 29 ng/mL)25(OH)D ≥125 nmol/L vs 25(OH)D 50 to 74 nmol/L | 18.1% (11.7%–24.6%) |
Prespecified subgroups
- Effect of vitamin D did not differ in prespecified subgroups
Safety
| Outcome | Estimate | |
|---|---|---|
| Adverse eventsVitamin Dvs PlaceboTrials may not have been powered for safety outcomes | rate ratio, kidney stones 1.17 (CI 0.69–1.99) | |
| Adverse eventsVitamin Dvs PlaceboTrials may not have been powered for safety outcomes | rate ratio, hypercalcemia 2.34 (CI 0.83–6.66) | |
| Adverse eventsVitamin Dvs PlaceboTrials may not have been powered for safety outcomes | rate ratio, hypercalciuria 1.65 (CI 0.83–3.28) | |
| Adverse eventsVitamin Dvs PlaceboTrials may not have been powered for safety outcomes | rate ratio, death 0.85 (CI 0.31–2.36) | |
| 0.10.31310Ratio (log scale) |
Adverse events
- No evidence of difference in rate ratios for adverse events
Original publication
Vitamin D and Risk for Type 2 Diabetes in People With Prediabetes : A Systematic Review and Meta-analysis of Individual Participant Data From 3 Randomized Clinical Trials. Ann Intern Med. Published 7 February 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →